AWARENESS

The general public doesn’t realize the magnitude of problems faced by children and adolescents with cancer and those who survive their cancers.  The Awareness Interest Group seeks to shine the spotlight on facts, such as:

  • Childhood cancer is the leading cause of death by disease among children and adolescents in the United States.
  • Most causes of childhood cancer are unknown and not preventable.
  • The incidence of childhood cancer is on the increase.
  • Most survivors will experience significant debilitating complications that result from their treatment regimes.
  • Children and adolescents who have or have had cancer are much more likely (more than 60%) to face bullying than their healthy classmates.
  • Only four drugs have been developed and approved to treat a pediatric cancer in the last quarter century.

CAC2 member organizations with an interest in Awareness are encouraged to participate in the work of the CAC2 Advocacy and Awareness Interest Group. Notes from the 2019 meeting of the working group are available here. Email if you would like more information on how to be involved with CAC2 awareness initiatives.

Raising awareness is crucial to increasing research funds and legislative efficacy.
Collaborating amplifies our impact.

Latest CAC2 and Community News

CAC2 Childhood Cancer Community News Digest (January 13-19)

Assorted News from the Last Week: The U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as a companion diagnostic for Supporting Organization Member Day One Biopharmaceuticals’ OJEMDA, a type II RAF inhibitor, for the treatment of patients six months of ...

CAC2 Childhood Cancer Community News Digest (January 6-12)

Assorted News from the Last Week: Pope Francis tells pediatric cancer patients they are ‘witnesses of hope.’ Unraveling the relationship between stress exposure and childhood anxiety: Considering accumulation, impact, and type in the first five years of life. New symptom ...

CAC2 Childhood Cancer Community News Digest (December 30-January 5)

Assorted News from the Last Week: GLO-BNHL opens first sites of a multi-country platform trial that will offer multiple new treatments and a better chance of survival for pediatric B-cell Non-Hodgkin lymphoma patients. Read more about this trial from a ...